The visual system has increasingly been recognized as an important site of injury in patients with schizophrenia and other psychoses. Visual system alterations manifest as visual perceptual aberrations, deficits in visual processing, and visual hallucinations. These visual symptoms are associated with worse symptoms, poorer outcome and resistance to treatment. A recent study using brain lesion mapping of visual hallucinations and identified a causal location in the part of the brain that processes visual information (visual cortex). The association between visual cortex activation and visual hallucinations suggests that this region could be targeted using noninvasive brain stimulation. Two case studies have found that brain stimulation to the visual cortex improved visual hallucinations in treatment resistant patients with psychosis. While promising it is unclear whether these symptom reductions resulted from activity changes in the visual cortex or not. Here we aim to answer the question whether noninvasive brain stimulation when optimally targeted to the visual cortex can improve brain activity, visual processing and visual hallucinations. The knowledge gained from this study will contribute to the field of vision by providing a marker for clinical response and by personalizing treatment for patients with psychosis suffering from visual symptoms. This grant will allow us to set the foundation for a larger more targeted study utilizing noninvasive brain stimulation to improve visual symptoms in patients with psychosis.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Steady State Visual Evoked Potential (ssVEP)
Timeframe: Measured at day 5 compared to day 0
Steady State Visual Evoked Potential (ssVEP)
Timeframe: Measured at day 30 compared to day 0 and day 5
Positive and Negative Syndrome Scale (PANSS)
Timeframe: Measured at day 5 compared to day 0
Positive and Negative Syndrome Scale (PANSS)
Timeframe: Measured at day 30 compared to day 0 and day 5
Biological Motion
Timeframe: Measured at day 5 compared to day 0
Biological Motion
Timeframe: Measured at day 30 compared to day 0 and day 5